Last reviewed · How we verify

Treatment of acute, uncomplicated Plasmodium falciparum malaria — Treatment Landscape & Competitive Intelligence

Treatment of acute, uncomplicated Plasmodium falciparum malaria (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Treatment of acute, uncomplicated Plasmodium falciparum malaria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
artesunate-amodiaquine (AS-AQ) artesunate-amodiaquine (AS-AQ) Yale University Artemisinin derivative + aminoquinoline antimalarial combination Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Yale University · 1 drug in Treatment of acute, uncomplicated Plasmodium falciparum malaria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment of acute, uncomplicated Plasmodium falciparum malaria:

Cite this brief

Drug Landscape (2026). Treatment of acute, uncomplicated Plasmodium falciparum malaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-acute-uncomplicated-plasmodium-falciparum-malaria. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing